Skip to content

A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain

Not yet recruitingNot applicableNCT07800676
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Evaluate the effect of A+HA premium oral hyaluronic acid drink on relieving knee pain.

Study details

Official title
A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
Interventions
Sponsor
Taipei Medical University
Collaborators
Z-Plus Biotechnology Co., Ltd.
Start date
2026-09-01
Primary completion
2027-01-31
Sex
All
Age range
from 45 Years to 80 Years
Results posted
No results posted in this snapshot
Countries
Taiwan
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Aged 45 to 80 years. 2. Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade \<3. 3. A Visual Analogue Scale (VAS) pain score ≤3. 4. A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score \>2 or a total WOMAC score \>12. Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Individuals with a history of knee joint trauma or surgery. 3. A body mass index (BMI) ≥ 40 kg/m². 4. Individuals with a psychiatric disorder. 5. Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer. 6. Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort. 7. Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial. 8. Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial. 9. Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures. 10. Any other condition considered by the physician to make the individual unsuitable for participation in the trial.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07800676